Japan Palmoplantar Pustulosis (PPP) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Palmoplantar Pustulosis (PPP) Market Size

• The Japan palmoplantar pustulosis (PPP) market size was valued at USD 153.56 million in 2024 and is expected to reach USD 250.35 million by 2032, at a CAGR of 6.30% during the forecast period
• The market growth is largely fueled by the increasing prevalence of Palmoplantar Pustulosis (PPP), rising awareness about effective treatment options, and the ongoing development of innovative therapeutics. These factors are driving adoption in both hospital and outpatient settings
• Furthermore, growing patient demand for safe, effective, and convenient treatment solutions is establishing advanced PPP therapies as the preferred choice among healthcare providers and patients. The development of targeted biologics, topical therapies, and combination treatment approaches is significantly contributing to the market’s expansion

Palmoplantar Pustulosis (PPP) Market Analysis

• Palmoplantar Pustulosis (PPP) is a chronic, inflammatory skin condition characterized by recurrent pustules (small pus-filled blisters) on the palms of the hands and soles of the feet, often associated with redness, scaling, and discomfort, and can significantly impact patients’ quality of life
• The escalating demand for PPP treatments in Japan is primarily fueled by an increasing prevalence of the condition, rising disposable incomes, and a growing preference for advanced therapeutic options
• Japan experienced substantial growth in palmoplantar pustulosis treatment adoption in 2024, particularly in urban centers and specialized dermatology clinics, driven by innovations from both established pharmaceutical companies and local startups focusing on novel therapies
• Adults segment dominated the Japan palmoplantar pustulosis (PPP) market in 2024 with market share of 70%, as palmoplantar pustulosis primarily affects adults who seek timely medical attention

Report Scope and Palmoplantar Pustulosis (PPP) Market Segmentation      

Palmoplantar Pustulosis (PPP) Market Trends

Rising Adoption of Advanced Therapeutic Options and Personalized Care in the Japan PPP Market

• A significant and accelerating trend in the Japan Palmoplantar Pustulosis (PPP) market is the increasing adoption of advanced therapeutic options, including both topical and systemic treatments. This trend is improving patient outcomes and driving growth in the overall market
  • For instance, new biologic therapies introduced in 2024 have demonstrated enhanced efficacy in managing PPP symptoms, allowing dermatologists to provide more targeted and long-term treatment solutions for Japanese patients
• Increased focus on patient education and awareness programs is enabling earlier diagnosis and treatment initiation, which is expected to reduce the severity and recurrence of PPP episodes in the population
• The expansion of specialized dermatology clinics and healthcare infrastructure across Japan facilitates greater access to PPP treatments, particularly in urban centers, helping meet rising patient demand
• This trend toward more personalized and effective treatment options is reshaping expectations in the Japanese PPP market, encouraging pharmaceutical companies to invest in research and localized clinical trials
• The demand for well-established PPP therapies, including the most widely used treatment segment, continues to grow in Japan, with this segment holding an estimated 43.2% market share in 2024, driven by its proven efficacy and widespread clinical adoption
• Growing collaboration between Japanese pharmaceutical companies and international research institutions is fostering the development of innovative PPP therapies and clinical trials tailored for the local population
• Increasing insurance coverage and reimbursement support for PPP treatments in Japan is enhancing treatment accessibility and affordability, further accelerating market growth

Palmoplantar Pustulosis (PPP) Market Dynamics

Driver

Growing Need Due to Rising Prevalence and Awareness of Palmoplantar Pustulosis (PPP)

• The increasing prevalence of Palmoplantar Pustulosis (PPP), coupled with rising awareness among patients and healthcare providers, is a significant driver for the heightened demand for effective treatment options
  • For instance, in April 2024, AbbVie Inc. announced new clinical data supporting guselkumab (Tremfya) for the treatment of PPP in Japanese patients. Such advancements by key companies are expected to drive the PPP industry growth during the forecast period.
• As patients and clinicians become more aware of the impact of PPP on quality of life, there is growing demand for therapies that provide sustained symptom relief, reduce flare-ups, and improve overall patient outcomes
• Furthermore, the rising emphasis on personalized and targeted treatment approaches is increasing the adoption of advanced biologics, topical therapies, and combination treatment regimens
• The convenience, efficacy, and safety profile of newer therapies, along with expanded access through hospitals, specialty clinics, and homecare programs, are key factors propelling the adoption of PPP treatments across Japan. The trend towards patient-centric care and greater healthcare accessibility further contributes to market growth

Restraint/Challeng

Concerns Regarding Side Effects, Accessibility, and Treatment Costs

• The adoption of Palmoplantar Pustulosis (PPP) therapies is often hindered by concerns surrounding potential side effects and long-term safety. Many patients and healthcare providers remain cautious about initiating or switching treatments without comprehensive clinical evidence, particularly for newer biologics or combination regimens. These safety concerns can impact prescription patterns, delaying treatment uptake and affecting market growth
• Accessibility of advanced therapies also poses a challenge. While urban hospitals and specialty clinics in Japan are well-equipped to provide cutting-edge PPP treatments, patients in rural or remote regions may face difficulties accessing these therapies due to limited availability of specialized care or trained healthcare professionals
• High treatment costs are another significant barrier. Advanced biologics and targeted therapies, while clinically effective, often come with a premium price, making them less affordable for certain patient groups or those without comprehensive insurance coverage. Even with generic or alternative therapies available, the perceived high cost of innovative treatments can deter patients from initiating or continuing therapy
• Overcoming these challenges requires a multi-faceted approach: robust clinical evidence to ensure patient and physician confidence, expanded healthcare access through more hospitals, specialty clinics, and homecare programs, and affordable pricing strategies or insurance support to broaden patient reach. Addressing these factors is essential for driving sustained adoption and growth in the Japan PPP market

Palmoplantar Pustulosis (PPP) Market Scope

The market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end-users, and distribution channel.

• By Disease Type

On the basis of disease type, the Japan palmoplantar pustulosis (PPP) market is segmented into Type A and Type B. The Type A segment dominated the market in 2024, with an estimated revenue share of 57%, due to its higher prevalence among Japanese patients and established treatment protocols. Type A responds effectively to conventional therapies such as topical steroids and emollients, which are widely prescribed in both urban and regional clinics. Awareness programs and patient education campaigns primarily focus on Type A, encouraging early diagnosis and treatment. Standardized treatment plans for Type A cases support consistent adoption across hospitals, specialty clinics, and homecare. Insurance coverage and hospital pharmacy availability further reinforce its leading position. Strong physician familiarity, clinical guidelines, and government health programs continue to prioritize Type A, maintaining its market dominance. Ongoing monitoring and follow-up mechanisms ensure patient adherence and steady revenue generation.

The Type B segment is expected to witness the fastest growth with a CAGR of 7.5% from 2025 to 2032, driven by increasing recognition of previously underdiagnosed or atypical cases. Type B often requires advanced treatment approaches, including phototherapy and systemic therapies. Hospitals and specialty clinics are expanding diagnostic and treatment capacity to manage these cases. Increased awareness among dermatologists and patients encourages early detection. Clinical trials and research studies targeting Type B support the development of innovative therapies. Urban hospitals and regional clinics are implementing new screening protocols to improve adoption. Homecare services are also expanding for Type B patients, supporting treatment adherence. Educational campaigns and patient support programs contribute to increasing uptake and rapid growth of this segment.

• By Severity

On the basis of severity, the Japan palmoplantar pustulosis (PPP) market is segmented into mild-moderate and moderate-severe. The mild-moderate segment dominated in 2024 with market share of 62%, supported by the high proportion of patients presenting with manageable symptoms. These cases respond well to topical therapies like steroids, emollients, and coal tar, which are widely prescribed by dermatologists. Mild-Moderate cases are easier to manage in outpatient settings, increasing accessibility through hospitals, specialty clinics, and homecare. Early diagnosis programs in urban and semi-urban areas target this population, ensuring timely treatment and reducing progression risk. High patient adherence and familiarity with treatment regimens strengthen dominance. Insurance coverage facilitates affordability, while hospital pharmacies, retail outlets, and online channels enhance distribution. Patient satisfaction and consistent treatment outcomes further reinforce this segment’s revenue position.

The moderate-severe segment is expected to witness the fastest growth with a CAGR of 8%, driven by rising prevalence of severe cases requiring combination or advanced therapies. Moderate-Severe patients increasingly receive phototherapy, systemic treatments, or biologics, promoting adoption in hospitals and specialty clinics. Awareness programs highlight the importance of intensive management. Insurance reimbursement encourages uptake of advanced therapies. Urban centers report higher volumes of severe cases, creating demand for specialized care. Homecare and hospital services are adapting to provide continuous monitoring. Clinical trials and innovative therapies for Moderate-Severe cases support rapid growth. Education initiatives targeting patients and caregivers further improve compliance and outcomes.

• By Diagnosis

On the basis of diagnosis, the Japan palmoplantar pustulosis (PPP) market is segmented into laboratory tests and skin biopsy. The laboratory tests segment dominated in 2024 with market share of 60%, due to non-invasive nature, affordability, and suitability for routine monitoring. Blood panels and inflammatory marker tests enable physicians to track disease progression efficiently. Hospitals and specialty clinics are well-equipped to perform laboratory diagnostics. These tests support timely treatment initiation and facilitate follow-up evaluations. Patient comfort and acceptance are higher compared to invasive methods. Hospital pharmacies and integrated diagnostic centers ensure strong availability. Routine screening programs and insurance coverage further reinforce the segment’s dominance. Continuous emphasis on laboratory diagnostics maintains a steady flow of patients into treatment pathways.

The skin biopsy segment is expected to witness the fastest growth with a CAGR of 7%, as clinicians increasingly use biopsies for severe or atypical cases. Biopsies provide precise pathological insights, enabling personalized treatment plans. Hospitals and specialty clinics are expanding biopsy services to meet demand. Advances in techniques make procedures safer and faster. Dermatologists’ increased awareness of biopsy benefits encourages adoption. Clinical studies validating biopsy-guided treatments boost confidence. Pediatric and adult patients benefit from accurate diagnosis. Homecare providers occasionally integrate biopsy results for personalized monitoring. Rising adoption, clinical validation, and patient acceptance drive rapid growth of this segment.

• By Treatment

On the basis of treatment, the Japan palmoplantar pustulosis (PPP) market is segmented into emollients, topical steroids, coal tar, and phototherapy. The topical steroids segment dominated in 2024 with market share of 55%, due to high efficacy, physician familiarity, and wide availability. Steroids provide fast relief of inflammation and pustules, prescribed in outpatient and homecare settings. Hospital pharmacies, retail, and online channels enhance accessibility. High patient adherence, simple application, and favorable outcomes reinforce dominance. Clinical guidelines favor topical steroids, and awareness campaigns educate patients on proper use. Insurance coverage and affordability further strengthen the segment. Continued research supports long-term safety and efficacy, maintaining its leading market position.

The Phototherapy segment is expected to witness the fastest growth with a CAGR of 8%, fueled by increasing adoption for moderate-severe cases unresponsive to topical therapies. Hospitals and specialty clinics are expanding phototherapy facilities. New technologies improve treatment efficiency and safety. Urban patients have better access, while awareness programs encourage uptake. Insurance coverage supports affordability. Homecare and outpatient centers provide treatment monitoring. Clinical studies demonstrate long-term efficacy. Patient preference for non-drug options contributes to growth. Overall, phototherapy adoption is rising steadily across Japan.

• By Population Type

On the basis of population type, the Japan palmoplantar pustulosis (PPP) market is segmented into children and adults. The Adults segment dominated in 2024 with market share of 70%, as PPP primarily affects adults who seek timely medical attention. Adults have access to a wide range of treatments including topical, systemic, and phototherapy. Awareness programs improve diagnosis rates, while hospital and clinic infrastructure supports treatment. Physician familiarity ensures high adherence. Urban adoption is highest, with regional hospitals maintaining steady access. Insurance coverage and hospital pharmacy availability reinforce dominance. Ongoing research guides therapy optimization. Adults’ engagement with healthcare providers sustains market growth.

The children segment is expected to witness the fastest growth with a CAGR of 6.5%, driven by recognition of pediatric PPP and demand for child-friendly formulations. Hospitals and clinics adopt specialized dosing regimens. Parental awareness programs enhance early diagnosis. Pediatricians and dermatologists focus on effective management. Homecare services support therapy adherence. Urban clinic visits for children are increasing. Clinical trials and educational campaigns for caregivers improve compliance. Rising awareness and innovation drive rapid segment growth. Government initiatives and pediatric healthcare programs are also supporting increased access and treatment adoption for children.

• By Route of Administration

On the basis of route of administration, the Japan palmoplantar pustulosis (PPP) market is segmented into oral, topical, and parenteral. The topical segment dominated in 2024 with market share of 60%, due to convenience, high adherence, and effectiveness. Treatments like emollients, coal tar, and steroids are widely prescribed. Accessibility through hospitals, clinics, and pharmacies strengthens adoption. Patients prefer localized symptom management. Clinical guidelines and proven outcomes reinforce dominance. Insurance coverage ensures affordability. Urban and regional hospitals provide consistent access. Continuous physician education supports proper use.

The parenteral segment is expected to witness the fastest growth with a CAGR of 7%, driven by biologics and systemic therapies for moderate-severe cases. Hospitals expand infrastructure for administration. Clinical research supports new therapy adoption. Patient awareness and acceptance are increasing. Insurance coverage for advanced biologics facilitates uptake. Specialty clinics and homecare integrate therapy monitoring. Urban hospitals lead adoption. Innovation and efficacy drive rapid segment growth. Ongoing clinical trials and development of next-generation biologics are expected to further accelerate adoption in the coming years.

• By End-Users

On the basis of end-users, the Japan palmoplantar pustulosis (PPP) market is segmented into hospitals, homecare, specialty clinics, and others. The Hospitals segment dominated in 2024 with market share of 65%, due to high patient volumes, availability of advanced treatments, and specialist dermatologists. Hospitals provide routine and advanced therapies, ensuring access in urban and regional areas. Trained staff, insurance coverage, and infrastructure reinforce dominance. Government and private initiatives promote treatment availability. Patient follow-up and adherence monitoring support outcomes. Hospitals serve as referral centers. Continuous physician training ensures quality care.

The specialty clinics segment is expected to witness the fastest growth with a CAGR of 8%, supported by increasing dermatology-focused clinics offering personalized therapies. Rapid appointments, targeted treatments, and patient-centric services encourage visits. Adoption of phototherapy, biologics, and combination therapies is higher. Education and follow-ups improve compliance. Partnerships with hospitals and research institutions support innovation. Clinics focus on early diagnosis and preventive care. Insurance coverage and service expansion further fuel growth. Convenience and specialized care drive adoption.

• By Distribution Channel

On the basis of distribution channel, the Japan palmoplantar pustulosis (PPP) market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated in 2024 with market share of 60%, as most treatments are prescribed and dispensed within hospital settings. Hospitals support conventional and advanced therapies. Urban and regional hospitals provide consistent access. Insurance coverage ensures affordability. Hospital pharmacies facilitate patient education and adherence. Trained staff maintain dispensing accuracy. Integration with clinical protocols reinforces dominance. Follow-up support ensures treatment effectiveness.

The online pharmacy segment is expected to witness the fastest growth with a CAGR of 9%, driven by convenience, digital adoption, and telemedicine services. Home delivery of topical therapies, steroids, and emollients is increasing. Regulatory frameworks support safe dispensing. Online pharmacies reach semi-urban and remote areas. Younger, tech-savvy patients adopt online channels rapidly. Integration with digital health platforms improves engagement and adherence. Insurance coverage encourages use. Awareness campaigns promote adoption. Flexibility and convenience drive rapid growth.

Palmoplantar Pustulosis (PPP) Market Regional Analysis

• Japan experienced notable growth in the palmoplantar pustulosis (PPP) market in 2024, with increasing adoption of treatments concentrated in urban centers and specialized dermatology clinics
• This growth has been driven by innovations from both well-established pharmaceutical companies and local startups developing novel therapies tailored to the needs of Japanese patients
• In 2024, Japan accounted for 10% of the global PPP market, reflecting a combination of rising patient awareness, enhanced healthcare infrastructure, and the active presence of key pharmaceutical players introducing advanced treatment options.
• The expansion of specialized dermatology clinics and improved access to healthcare services has facilitated broader treatment adoption, particularly for advanced biologics and combination therapy regimens
• Moreover, increasing insurance coverage and reimbursement support have improved treatment affordability and accessibility, enabling a larger segment of the patient population to benefit from effective PPP therapies
• These factors collectively underscore the country’s growing role in the global PPP market and highlight the continued investment and focus by pharmaceutical companies in Japan

Palmoplantar Pustulosis (PPP) Market Share

The Palmoplantar Pustulosis (PPP) industry is primarily led by well-established companies, including:

• Amgen Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Johnson & Johnson and its affiliates (U.S.)
• AnGes, Inc. (Japan)
• Kyowa Kirin Co., Ltd. (Japan)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Boehringer Ingelheim GmbH (Germany)
• Novartis AG (Switzerland)
• Lilly USA, LLC (U.S.)
• AnaptysBio, Inc. (U.S.)
• LEO Pharma A/S (Denmark)

Latest Developments in Japan Palmoplantar Pustulosis (PPP) Market

• In August 2023, Kyowa Kirin received partial change approval from Japan’s Ministry of Health, Labour and Welfare for LUMICEF (brodalumab), a fully human anti-IL-17 receptor A antibody. This approval was based on the results of a Phase 3 clinical trial demonstrating its efficacy in treating PPP patients who had an inadequate response to existing therapies. LUMICEF is the first IL-17 pathway inhibitor approved for PPP in Japan
• In March 2025, a randomized Phase 3 study (JumPPP) demonstrated that RZB (risankizumab), an IL-23 inhibitor, significantly improved PPP symptoms in Japanese patients. The treatment showed sustained efficacy through week 68 and was well tolerated, indicating its potential as a new therapeutic option for PPP in Japan
• In May 2025, a Phase 3 trial in Japan demonstrated the significant efficacy of apremilast in treating PPP, with a favorable safety profile. This suggests that apremilast could be a viable treatment option for PPP patients in Japan
• In June 2025, Japan's Cabinet approved the Integrated Innovation Strategy, emphasizing international collaboration in scientific research. This strategy aims to enhance research and development in various medical fields, potentially benefiting the PPP market by fostering innovation and the development of new treatments
• In August 2025, Japan's Ministry of Health, Labour and Welfare invested an additional USD 1 million to support the Global Antibiotic Research and Development Partnership (GARDP) from April 2025 to March 2026. This funding aims to support discovery and exploratory research to identify new antibiotic candidates and help develop new and improved treatments for infections, indirectly supporting advancements in dermatological treatments, including those for PPP

SKU-58673